Rhovac wants to raise more than a million dollars on the stock exchange
The listed Danish company Rhovac issues new shares for up to USD 3 million, which will finance new research activities as well as speed up the company's search for a potential buyer for its cancer vaccine.
Danish biotech company Rhovac has announced that it will concentrate on selling parts of, or all of the business in 2018. Paradoxically, that involves planning for the future.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
